Even though PPARα ligands could be used to combat hepatic steatosis in non-alcoholic fatty liver disease (NAFLD), it is evident that PPARα ligands reduce liver fat in rodents19, 20, but not necessarily in humans21. This evidence concerns the gene PPARA and fatty liver disease.